Folfirinox

Phase 3Small molecule

PPhanes Therapeutics

Folfirinox is one of 285 small molecule programs targeting Pancreatic Carcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

284

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic CarcinomaActive, not recruiting

MetastasisActive, not recruiting

AdenocarcinomaActive, not recruiting

Neuroendocrine CarcinomaActive, not recruiting

Pancreatic Ductal AdenocarcinomaActive, not recruiting

Pancreatic AdenocarcinomaActive, not recruiting

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Gastric CancerActive, not recruiting

CholangiocarcinomaActive, not recruiting

Pancreatic CarcinomaPhase 1

Active, not recruiting

MetastasisPhase 2

Active, not recruiting

AdenocarcinomaPhase 2

Active, not recruiting

Neuroendocrine CarcinomaPhase 2

Active, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 1

Active, not recruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

Colorectal CancerPhase 3

Active, not recruiting

Pancreatic CancerPhase 2

Active, not recruiting

Gastric CancerPhase 2

Active, not recruiting

CholangiocarcinomaPhase 2

Active, not recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Folfirinox

PPhanes Therapeutics

Phase 3

25 2

Byetta

AstraZeneca

Preclinical

1 3

ABI-007

Bristol-Myers Squibb

Preclinical

2 4

LDE225

Novartis

Preclinical

1 5

Sulfonylureas

Eli Lilly

Preclinical

1 6

Thiazolidinediones

Sanofi

Preclinical

1 7

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 8

Meglitinides

Sanofi

Preclinical

1 9

Chemotherapy Agents

Takeda

Preclinical

1 10

Active Comparator

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Active, not recruiting

Pancreatic Cancer

NCT05360732

Phase 1/2Active, not recruiting

Neoadjuvant

NCT05121038

Q4 2026

Phase 2Recruiting

Gastric Cancer

NCT03825861

Q2 2027

Phase 2Active, not recruiting

Pancreatic Cancer

NCT03563248

Phase 2Recruiting

Pancreatic Cancer

NCT05132504

Q3 2027

Phase 1Recruiting

Pancreatic Adenocarcinoma

NCT03484299

Clinical

Trials by Indication[1]

Pancreatic Cancer25 trials

Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer

Terminated·NNewLink Genetics Corporation·Phase 3·NCT01836432·302 enrolled

mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients

Recruiting·SSun Yat-sen University·Phase 2·NCT04084496·80 enrolled

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 2·NCT05462496·25 enrolled

Show 22 more trials

Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer

Withdrawn·IIndiana University·Phase 2·NCT04130399

Effects of Folfirinox and Stereotactic Body Radiation Therapy for Advanced Pancreatic Cancer

Completed·UUniversity of Louisville·Phase 2·NCT02128100·5 enrolled

FOLFIRINOX Followed by Ipilimumab With Pancreatic Tumor Vaccine in Treatment of Metastatic Pancreatic Cancer

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01896869·83 enrolled

Observational Retrospective Study of Evaluation of Prognostic Factors in Advanced Pancreatic Cancer Patients Treated With FOLFIRINOX

Completed·AAzienda Ospedaliero, Universitaria Pisana··NCT03590275·343 enrolled

FOLFIRINOX + RT for Pancreatic Cancer

Unknown status·MMassachusetts General Hospital·Phase 2·NCT01591733·48 enrolled

Neoadjuvant FOLFIRINOX or Nab-paclitaxel With Gemcitabine for Borderline Resectable Pancreatic Cancer

Unknown status·NNagoya University·Phase 2·NCT02717091·50 enrolled

FOLFIRINOX + NIS793 in Pancreatic Cancer

Terminated·—·Phase 1·NCT05417386·4 enrolled

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Terminated·MMassachusetts General Hospital·Phase 2·NCT02243007·7 enrolled

Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)

Recruiting·AAmsterdam UMC, location VUmc·Phase 1/2·NCT06384560·66 enrolled

Study of Modified FOLFIRINOX in Advanced Pancreatic Cancer

Completed·YYale University·Phase 2·NCT01523457·75 enrolled

Folfirinox or Gemcitabine-Nab Paclitaxel Followed by Stereotactic Body Radiotherapy for Locally Advanced Pancreatic Cancer

Terminated·UUniversity of Alabama at Birmingham·Phase 1·NCT03600623·25 enrolled

Losartan and Nivolumab in Combination With FOLFIRINOX and SBRT in Localized Pancreatic Cancer

Active, not recruiting·MMassachusetts General Hospital·Phase 2·NCT03563248·168 enrolled

Gemcitabine+Nab-paclitaxel and FOLFIRINOX and Molecular Profiling for Patients With Advanced Pancreatic Cancer

Completed·PPancreatic Cancer Research Team·Phase 1/2·NCT01488552·60 enrolled

NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)

Recruiting·SSeoul National University Hospital·Phase 3·NCT05529940·609 enrolled

Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer

Unknown status·—·Phase 3·NCT04897854·184 enrolled

A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer

Unknown status·SSilenseed Ltd·Phase 2·NCT01676259·80 enrolled

First-line Metastatic Pancreatic Cancer : FOLFIRINOX +/- LV5FU2 in Maintenance Versus Firgem

Completed·FFederation Francophone de Cancerologie Digestive·Phase 2·NCT02352337·276 enrolled

Redefining FOLFIORINOX in Older Pancreatic Cancer Patients

Active, not recruiting·FFox Chase Cancer Center·Phase 2·NCT05360732·37 enrolled

Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer (NORPACT-2)

Active, not recruiting·OOslo University Hospital··NCT04423731·251 enrolled

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer

Recruiting·—·Phase 2·NCT05132504·30 enrolled

FOLFIRINOX for Unresectable Locally Advanced and Borderline Resectable Pancreatic Cancer

Terminated·UUNC Lineberger Comprehensive Cancer Center·Phase 2·NCT01688336·9 enrolled

Proton w/FOLFIRINOX-Losartan for Pancreatic Cancer

Unknown status·MMassachusetts General Hospital·Phase 2·NCT01821729·50 enrolled

Pancreatic Adenocarcinoma7 trials

First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma.

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 1/2·NCT01964287·78 enrolled

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma

Active, not recruiting·UUniversity of Cincinnati·Phase 2·NCT04594772·32 enrolled

Pancreatic Adenocarcinoma Signature Stratification for Treatment

Completed·UUniversity Health Network, Toronto·Phase 2·NCT04469556·150 enrolled

Show 4 more trials

Chemotherapy and Irreversible Electroporation in the Treatment of Advanced Pancreatic Adenocarcinoma

Recruiting·UUniversity of Louisville·Phase 1·NCT03484299·20 enrolled

Study of FOLFIRINOX Electrochemotherapy in the Treatment of Pancreatic Adenocarcinoma

Withdrawn·TThe University of Texas Health Science Center, Houston·Phase 1·NCT02592395

A Randomized Phase II/Genomic Trial of Two Chemotherapy Regimens in Patients With Resected Pancreatic Adenocarcinoma

Completed·—·Phase 2·NCT01839799·32 enrolled

Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study

Terminated·UUniversity of Chicago·Phase 1·NCT02782182·1 enrolled

Neoadjuvant2 trials

A Phase II Study of Neoadjuvant FOLFIRINOX

Completed·IIndiana University·Phase 2·NCT02178709·48 enrolled

CEND-1 in Combination with Neoadjuvant FOLFIRINOX with or Without Panitumumab

Active, not recruiting·AAnup Kasi·Phase 1/2·NCT05121038·50 enrolled

Pancreatic Ductal Adenocarcinoma2 trials

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Completed·CCantargia AB·Phase 1·NCT04990037·25 enrolled

Eryaspase With Modified FOLFIRINOX in Advanced Pancreatic Ductal Adenocarcinoma

Completed·GGeorgetown University·Phase 1·NCT04292743·19 enrolled

Adenocarcinoma2 trials

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Completed·CCornerstone Pharmaceuticals·Phase 3·NCT03504423·528 enrolled

Pancreatic Tumor Cell Vaccine (GVAX), Cyclophosphamide, SBRT, and FOLFIRINOX in Patients With Resected Adenocarcinoma of the Pancreas

Completed·SSidney Kimmel Comprehensive Cancer Center at Johns Hopkins·Phase 2·NCT01595321·19 enrolled

16 more indications

Neuroendocrine Carcinoma1 trial

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Terminated·HH. Lee Moffitt Cancer Center and Research Institute·Phase 2·NCT03042780·2 enrolled

Cholangiocarcinoma1 trial

Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma

Completed·—·Phase 2·NCT02456714·30 enrolled

Total Neoadjuvant Therapy1 trial

Brazilian Total Neoadjuvant Therapy Trial

Unknown status·HHospital Israelita Albert Einstein·Phase 3·NCT05081687·150 enrolled

Nab-paclitaxel1 trial

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

Recruiting·UUNC Lineberger Comprehensive Cancer Center·Phase 1/2·NCT06483555·104 enrolled

Gemcitabine1 trial

A Study of Neoadjuvant FOLFIRINOX and FDR-Gemcitabine With Concurrent IMRT in Patients

Completed·UUniversity of Michigan Rogel Cancer Center·Phase 2·NCT01661088·25 enrolled

Locally Advanced1 trial

Pancreatic Locally Advanced Irresectable Cancer Ablation

Unknown status·—·N/A·NCT03690323·228 enrolled

Sorafenib1 trial

HAIC of FOLFOX Plus Sorafenib vs HAIC of FOLFIRINOX Plus Sorafenib for Advcanced HCC

Unknown status·SSun Yat-sen University·Phase 2·NCT03812783·100 enrolled

First-line Treatment1 trial

ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study

Completed·AAbility Pharmaceuticals SL·Phase 1/2·NCT04431258·150 enrolled

Metastasis1 trial

Systemic Chemotherapy Plus PD-1 for Metastasis ICC

Withdrawn·SSun Yat-sen University·Phase 2·NCT04398927

Prospective1 trial

A Multicenter Prospective Phase II Study of Modified FOLFIRINOX for 1st Line Treatment for Advanced Urachus Cancer

Unknown status·—·Phase 2·NCT04611724·35 enrolled

Pancreatic Carcinoma1 trial

Pressure Enabled Drug Delivery By Pancreatic Retrograde Venous Infusion For Advanced Pancreatic Carcinoma

Withdrawn·RRoger Williams Medical Center·Phase 1·NCT04270929

Gastric Cancer1 trial

Neoadjuvant FOLFIRINOX in the Treatment of Locally Advanced Gastric Cancer

Recruiting·IInstituto do Cancer do Estado de São Paulo·Phase 2·NCT03825861·27 enrolled

Colorectal Cancer1 trial

Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test

Not yet recruiting·UUNICANCER·Phase 3·NCT07340567·2,450 enrolled

Liver Metastases1 trial

Intensified Chemotherapy in CRC After Resection of Liver Metastases

Completed·IInstitut du Cancer de Montpellier - Val d'Aurelle·Phase 2/3·NCT00208260·124 enrolled

Adjuvant Chemotherapy1 trial

The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.

Recruiting·FFondazione Poliambulanza Istituto Ospedaliero··NCT06068023·400 enrolled

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

A Phase 1/2, Open-Label, Dose Escalation and Expansion Study With PT886 (Spevatamig) Followed by a Multi-cohorT Study in Patients With Advanced GastrIc, Gastroesophageal JuNction, Pancreatic Ductal or Biliary Tract AdEnocarcinomas of PT886, in Combination With ChemotherApy, and/or an Immune ChecKpoint Inhibitor. The TWINPEAK Study

Recruiting·PPhanes Therapeutics·Preclinical·NCT05482893·258 enrolled

Sources

References

[1]
ClinicalTrials.gov — 54 trial records for Folfirinox. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Folfirinox compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Folfirinox. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Phanes Therapeutics company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: PPhanes Therapeutics

Folfirinox

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q2 2027

Q3 2027

Trials by Indication[1]

Pancreatic Cancer25 trials

Pancreatic Adenocarcinoma7 trials

Neoadjuvant2 trials

Pancreatic Ductal Adenocarcinoma2 trials

Adenocarcinoma2 trials

Neuroendocrine Carcinoma1 trial

Cholangiocarcinoma1 trial

Total Neoadjuvant Therapy1 trial

Nab-paclitaxel1 trial

Gemcitabine1 trial

Locally Advanced1 trial

Sorafenib1 trial

First-line Treatment1 trial

Metastasis1 trial

Prospective1 trial

Pancreatic Carcinoma1 trial

Gastric Cancer1 trial

Colorectal Cancer1 trial

Liver Metastases1 trial

Adjuvant Chemotherapy1 trial

Gastric or Gastroesophageal Junction Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News